PMID- 26359024
OWN - NLM
STAT- MEDLINE
DCOM- 20151114
LR  - 20221207
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 54
IP  - 7
DP  - 2015 Jul
TI  - [Effectiveness and safety of initiation of once-daily insulin detemir in Chinese 
      patients with type 2 diabetes previously treated with different quantities of 
      oral anti-diabetic drugs: subgroup analysis of the Chinese SOLVE Study].
PG  - 612-7
AB  - OBJECTIVE: To evaluate the effectiveness and safety on once-daily (OD) insulin 
      detemir (IDet) in Chinese patients with type 2 diabetes mellitus (T2DM) who were 
      treated with different types or combinations of oral anti-diabetic drugs (OADs). 
      METHODS: The SOLVE study was a 24-week observational study on the initiation of 
      IDet OD in T2DM patients with uncontrolled hyperglycemia on diet, exercise, and 
      one or more OADs. Subjects were grouped based on the numbers of OADs taken before 
      (>2-OAD, 2-OAD, and 1-OAD groups). Efficacy and safety endpoints were evaluated 
      and compared in different groups. RESULTS: This study includes 3 272 patients, 
      among them 464 (14.2%) were treated with more than 2 OADs, 1511 (46.2%) with 2 
      OADs, and 1 218 (37.2%) with 1 OAD before the study. The mean glycosylated 
      hemoglobin A1c (HbA1c) was 8.4%, 8.3%, 8.4% at baseline, and 7.3%, 7.2%, 7.1% at 
      the end of 24-week in each 3 groups (all P<0.001 vs. baseline values). The HbA1c 
      reductions were not statistically significant different among groups. Body weight 
      tended to decrease in patients from all groups, however, only that in the 2-OAD 
      group reached statistically significance. No major hypoglycaemia events were 
      reported. However, the overall minor hypoglycaemia rate in the 2-OAD group was 
      higher at the end of the study than that at baseline (P<0.05). No differences in 
      the rate of nocturnal minor hypoglycaemia were observed in all groups after IDet 
      treatment. CONCLUSION: Initiation of IDet OD was effective and well-tolerated in 
      Chinese patients with T2DM whose glycemia was poorly controlled on OADs 
      irrespective of the number of OADs taken before. (registration number 
      NCT00825643).
FAU - Pan, Changyu
AU  - Pan C
AD  - Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, China; 
      Email: panchy301@126.com.
FAU - Ji, Linong
AU  - Ji L
FAU - Lu, Juming
AU  - Lu J
FAU - Yang, Wenying
AU  - Yang W
FAU - Zhou, Zhiguang
AU  - Zhou Z
CN  - Chinese SOLVE Study
LA  - chi
SI  - ClinicalTrials.gov/NCT00825643
PT  - Journal Article
PT  - Observational Study
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin, Long-Acting)
RN  - 4FT78T86XV (Insulin Detemir)
SB  - IM
MH  - Blood Glucose/*drug effects
MH  - China/epidemiology
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/ethnology
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hyperglycemia/drug therapy
MH  - Hypoglycemia
MH  - Hypoglycemic Agents/*administration & dosage/adverse effects
MH  - Insulin Detemir
MH  - Insulin, Long-Acting/*administration & dosage/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Treatment Outcome
EDAT- 2015/09/12 06:00
MHDA- 2015/11/15 06:00
CRDT- 2015/09/12 06:00
PHST- 2015/09/12 06:00 [entrez]
PHST- 2015/09/12 06:00 [pubmed]
PHST- 2015/11/15 06:00 [medline]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 2015 Jul;54(7):612-7.